Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517399 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01517399 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 28 participants.
The verdict
NCT01517399, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of tivantinib on the pharmacokinetics of omeprazole, s-warfarin, caffein, midazolam, or digoxin in patients with cancer.
Interventions
- DRUG omeprazole
- DRUG caffeine
- DRUG tivantinib
- DRUG s-warfarin
- DIETARY_SUPPLEMENT vitamin K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01517399
The ClinicalTrials.gov registry entry for NCT01517399 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which omeprazole is the first listed.
NCT01517399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01517399 about?
NCT01517399 is a clinical study titled "Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects". The purpose of this study is to determine the effects of tivantinib on the pharmacokinetics of omeprazole, s-warfarin, caffein, midazolam, or digoxin in patients with cancer.
What is the current status of trial NCT01517399?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-12. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01517399?
The interventions under investigation include: omeprazole (DRUG), caffeine (DRUG), tivantinib (DRUG), s-warfarin (DRUG), vitamin K (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01517399?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.